HomeCompareCLSN vs ABBV

CLSN vs ABBV: Dividend Comparison 2026

CLSN yields 102.74% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLSN wins by $4.25M in total portfolio value
10 years
CLSN
CLSN
● Live price
102.74%
Share price
$1.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.36M
Annual income
$1,494,304.71
Full CLSN calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CLSN vs ABBV

📍 CLSN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLSNABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLSN + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLSN pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLSN
Annual income on $10K today (after 15% tax)
$8,733.18/yr
After 10yr DRIP, annual income (after tax)
$1,270,159.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CLSN beats the other by $1,249,103.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLSN + ABBV for your $10,000?

CLSN: 50%ABBV: 50%
100% ABBV50/50100% CLSN
Portfolio after 10yr
$2.23M
Annual income
$759,538.23/yr
Blended yield
34.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CLSN
Analyst Ratings
6
Buy
2
Hold
1
Sell
Consensus: Buy
Altman Z
-7819.1
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLSN buys
0
ABBV buys
0
No recent congressional trades found for CLSN or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLSNABBV
Forward yield102.74%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.36M$102.3K
Annual income after 10y$1,494,304.71$24,771.77
Total dividends collected$3.90M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CLSN vs ABBV ($10,000, DRIP)

YearCLSN PortfolioCLSN Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$20,974$10,274.32$11,550$430.00+$9.4KCLSN
2$42,582$20,139.91$13,472$627.96+$29.1KCLSN
3$83,777$38,213.45$15,906$926.08+$67.9KCLSN
4$159,904$70,262.72$19,071$1,382.55+$140.8KCLSN
5$296,433$125,336.27$23,302$2,095.81+$273.1KCLSN
6$534,334$217,150.75$29,150$3,237.93+$505.2KCLSN
7$937,555$365,816.85$37,536$5,121.41+$900.0KCLSN
8$1,603,062$599,878.65$50,079$8,338.38+$1.55MCLSN
9$2,673,868$958,591.11$69,753$14,065.80+$2.60MCLSN
10$4,355,343$1,494,304.71$102,337$24,771.77+$4.25MCLSN

CLSN vs ABBV: Complete Analysis 2026

CLSNStock

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Full CLSN Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CLSN vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLSN vs SCHDCLSN vs JEPICLSN vs OCLSN vs KOCLSN vs MAINCLSN vs JNJCLSN vs MRKCLSN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.